Zobrazeno 1 - 10
of 144
pro vyhledávání: ''
Autor:
Hélène Senellart, Sung Bae Kim, Takashi Kojima, Antoine Adenis, Shukui Qin, Peter C. Enzinger, Jaafar Bennouna, Jia Chen, Toshihiko Doi, Jean-Philippe Metges, Ken Kato, Lin Shen, Christelle De La Fouchardiere, Kei Muro, Eric Francois, Toshikazu Moriwaki, Keynote Investigators, S. Peter Kang, Shailaja Suryawanshi, Se-Hoon Lee, Ruixue Wang, Raed Al-Rajabi, Florian Lordick, Paula Ferreira, Gustavo Girotto, Chih-Hung Hsu, Manish A. Shah, Pooja Bhagia
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(35)
PURPOSE Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. PATIENTS AND METHODS In this open-label, phase III study, we randomly assigned (1:1) 628 patients with advanced/metast
Autor:
Masakazu Toi, Joyce O'Shaughnessy, Investigators, Valentina Guarneri, Ran Wei, Maarten Hulstijn, Irfan Cicin, Mario Campone, Frances M. Boyle, Jens Huober, Patrick Neven, Erika Hamilton, Belen San Antonio, Morihito Okada, Sara M. Tolaney, Andrew M Wardley, Roberto Hegg, Desiree Headley, Stephen R. D. Johnston, Martin Frenzel, Q. Zhang, Priya Rastogi, Zhi Min Shao, Jorge Luis Martinez Rodriguez, Miguel Martín, Javier Cortes, Ian C. Smith, Nadia Harbeck, Joohyuk Sohn, Joanne Cox
Publikováno v:
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology
Càncer de mama precoç; Teràpia endocrina; Abemaciclib Cáncer de mama precoz; Terapia endocrina; Abemaciclib Early Breast Cancer; Endocrine Therapy; Abemaciclib PURPOSE Many patients with HR+, HER2− early breast cancer (EBC) will not experience
Autor:
Masahiro Kashiwaba, Tsuyoshi Saito, Michiko Tsuneizumi, Hiroji Iwata, Noriko Sagawa, Hiroaki Kawashima, Takuya Kawahara, Miki Yamaguchi, Yasuo Ohashi, Tsutomu Takashima, Masataka Sawaki, Toshiro Mizuno, Naruto Taira, Shinichi Baba, Yutaka Yamamoto, Hirofumi Mukai, Yukari Uemura, Takahiro Nakayama, Hiroko Bando, Masato Takahashi, Kokoro Kobayashi
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(32)
PURPOSE Adjuvant trastuzumab monotherapy has not been compared with trastuzumab + chemotherapy. We investigated the relative value of trastuzumab monotherapy for older patients with breast cancer. METHODS This study was an open-label, randomized cont
Autor:
Eric J. Small, Martin E. Gleave, Mary-Ellen Taplin, Saby George, Susan Halabi, Christopher P. Evans, David W. Hillman, Himisha Beltran, J. Kellogg Parsons, Olwen Hahn, James L. Mohler, Russell Z. Szmulewitz, Glenn Heller, Michael J. Morris, James A. Eastham, Martin G. Sanda, Jonathan A. Coleman, J. Paul Monk, Colleen Watt, Steven K. Clinton
Publikováno v:
J Clin Oncol
PURPOSERadical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would imp
Autor:
Vincent Audard, Felipe Suarez, Salomon Manier, Frank Bridoux, Cécile Vigneau, Karine Augeul-Meunier, Bertrand Joly, Lionel Karlin, Bertrand Arnulf, Mourad Tiab, Nina Arakelyan-Laboure, Sophie Caillard, Alexandre Karras, Nolwenn Rabot, K. Belhadj, Bruno Royer, Margaret Macro, Sébastien Delbès, Jean Paul Fermand, P. Gobert, Damien Roos-Weil, Brigitte Pegourie, Emilie Cornec-Le Gall, Sylvie Chevret, Nicolas Blin, Denis Caillot, Arnaud Jaccard
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(23)
PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for
Autor:
Mahmut Gumus, Alexander Luft, Parneet Cheema, Keynote Investigators, Julien Mazieres, M. Catherine Pietanza, Victoria Ebiana, Maya Gottfried, Mirjana Wollner, Francisco Orlandi, Hye Ryun Kim, Solange Peters, Tibor Csőszi, James Chih-Hsin Yang, Yiwen Luo, Charles M. Rudin, Alejandro Navarro, Delvys Rodriguez-Abreu, Gregory P. Kalemkerian, Terufumi Kato, Mark M. Awad
Publikováno v:
J Clin Oncol
PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for
Autor:
Heather A. Lankes, Sudarshan K. Sharma, Carol Aghajanian, Cara Mathews, Daniel J. Powell, Dmitriy Zamarin, Andrea R. Hagemann, Oliver Zivanovic, Camille C. Gunderson, Emily M. Ko, Samir N. Khleif, Robert A. Burger, Michael W. Sill, Michael Feldman
Publikováno v:
J Clin Oncol
PURPOSE Single-agent PD-1 blockade exhibits limited efficacy in epithelial ovarian cancer (EOC). We evaluated ipilimumab plus nivolumab compared with nivolumab alone in women with persistent or recurrent EOC. METHODS Eligibility criteria included mea
Autor:
Shuichi Hironaka, Hiroaki Tanioka, Kazuhiro Nishikawa, Yoshiki Horie, Junji Kawada, Takeharu Yamanaka, Kei Muro, Toshikazu Moriwaki, Hiroyasu Ishida, Tomomi Kashiwada, Ayumu Hosokawa, Taito Esaki, Narikazu Boku, Akihito Tsuji, Kentaro Yamazaki, Hiroshi Tsukuda, Yasutaka Sukawa, Keita Uchino, K. Shinozaki, Akitaka Makiyama, Ichinosuke Hyodo, Hirofumi Yasui
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(17)
PURPOSE This study evaluated the continuous use of trastuzumab beyond progression (TBP) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. PATIENTS AND METHODS Patients with HER2-
Autor:
Liqiang Xi, Robert J. Kreitman, Constance M. Yuan, Hong Zhou, Lacey R. James, Mark Raffeld, Hao-Wei Wang, Seth M. Steinberg, Katherine R. Calvo, Evgeny Arons, Wyndham H. Wilson, Alina Dulau-Florea, Julie Feurtado, Irina Maric, Raul C. Braylan, Dai Chihara, Maryalice Stetler-Stevenson
Publikováno v:
J Clin Oncol
PURPOSE Single-agent purine analog, usually cladribine, has been the standard first-line therapy of hairy cell leukemia (HCL) for 30 years. High complete remission (CR) rates often include minimal residual disease (MRD), leading to relapse and repeat
Autor:
Patrick G. Gavin, Saranya Chumsri, Alvaro Moreno-Aspitia, Zhuo Li, Edith A. Perez, Afshin Mashadi-Hossein, Daniel J. Serie, Soonmyung Paik, Nan Song, Katherine L. Pogue-Geile, E. Aubrey Thompson, Gerardo Colon-Otero
Publikováno v:
J Clin Oncol
PURPOSE Recent trials have shown potential benefit of extended adjuvant endocrine therapy and relatively high risk of recurrence (RoR) after 5 years in hormone receptor-positive (HR+) human epidermal growth factor receptor 2–negative (HER2−) brea